Scott W. Morrison - 15 Sep 2025 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Director
Signature
/s/ Scott Sieckert, Attorney-in-Fact
Issuer symbol
TARS
Transactions as of
15 Sep 2025
Net transactions value
$0
Form type
4
Filing time
16 Sep 2025, 16:06:27 UTC
Previous filing
26 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Morrison Scott W Director 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE /s/ Scott Sieckert, Attorney-in-Fact 16 Sep 2025 0001662426

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARS Common Stock Options Exercise +1,334 +40% 4,684 15 Sep 2025 Direct F1
holding TARS Common Stock 6,016 15 Sep 2025 By Morrison-Minton Family 2004 Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Restricted Stock Units Options Exercise $0 -1,334 -100% $0.000000 0 15 Sep 2025 Common Stock 1,334 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
F2 The Reporting Person is trustee of the Morrison-Minton Family 2004 Trust, and the Reporting Person and his spouse are the sole beneficiaries of the trust.
F3 The RSUs vested in three equal annual installments on September 15th of 2023, 2024, and 2025, subject to the Reporting Person's continuous service.